These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 20977926)

  • 1. The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
    Abeltino M; Bonomini S; Bolzoni M; Storti P; Colla S; Todoerti K; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2011 Jan; 39(1):55-65. PubMed ID: 20977926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of arsenic trioxide combined with bortezomib on proliferation, apoptosis and beta-catenin level in myeloma cell lines].
    Zhou LL; Fu WJ; Yuan ZG; Wang DX; Hou J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):84-8. PubMed ID: 18315906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].
    Cai YX; Meng FY; Sun QX; Fu YB; Li L
    Zhonghua Xue Ye Xue Za Zhi; 2008 Nov; 29(11):737-40. PubMed ID: 19176009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HL-60 cell apoptosis induced by bortezomib alone or in combination with arsenic trioxide in vitro].
    Sun QX; Meng FY; Fu YB; Li L; Tian S
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):1022-5. PubMed ID: 17666343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells.
    Elmahi AY; Niu C; Li W; Li D; Wang GJ; Hao SS; Cui JW
    Asian Pac J Cancer Prev; 2013; 14(11):6469-73. PubMed ID: 24377552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Synergistic effects of arsenic trioxide and proteasome inhibitor bortezomib on apoptosis induction in Raji cell line].
    He Y; Yang JM; Wang JM; Zhou H; Lü SQ; Hu XX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):794-8. PubMed ID: 18718063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of bortezomib alone or combined with arsenic trioxide on the apoptosis of Jurkat cells and expression of livin mRNA].
    Tan DW; Sun ZQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):898-901. PubMed ID: 21867610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
    Xu W; Wei W; Yu Q; Wu C; Ye C; Wu Y; Yan H
    Mol Med Rep; 2014 Sep; 10(3):1519-24. PubMed ID: 24939418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of arsenic trioxide combined with bortezomib on apoptosis of multiple myeloma cell line KM3 and its mechanisms.
    Ge QF; Ouyang GF; Chen Y; Zhang Y; Mu QT; Lu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):112-5. PubMed ID: 22391178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism].
    Wu HY; Wang SM; Huang JQ; Hao LM; Li XM; Wei LY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1361-4. PubMed ID: 23257433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of bortezomib used alone or in combination with arsenic trioxide on HL-60 cell xenograft in nude mice].
    Li L; Meng FY; Fu YB; Cai YX; Sun QX
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1504-6. PubMed ID: 17959525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib.
    Huang M; Thomas D; Li MX; Feng W; Chan SM; Majeti R; Mitchell BS
    Leukemia; 2013 Oct; 27(10):1970-80. PubMed ID: 23877794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic anticancer effects of arsenic trioxide with bortezomib in mantle cell lymphoma.
    Jung HJ; Chen Z; McCarty N
    Am J Hematol; 2012 Dec; 87(12):1057-64. PubMed ID: 22965904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
    Li CY; Meng FY; Sun QX; Fu YB; Li L; Yi ZS; Song LL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Nov; 27(11):1665-9. PubMed ID: 18024285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J; Van Valckenborgh E; Xu D; Menu E; De Raeve H; De Bruyne E; Xu S; Van Camp B; Handisides D; Hart CP; Vanderkerken K
    Mol Cancer Ther; 2013 Sep; 12(9):1763-73. PubMed ID: 23832122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
    Moschetta M; Di Pietro G; Ria R; Gnoni A; Mangialardi G; Guarini A; Ditonno P; Musto P; D'Auria F; Ricciardi MR; Dammacco F; Ribatti D; Vacca A
    Eur J Cancer; 2010 Jan; 46(2):420-9. PubMed ID: 19914061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
    Bruzzese F; Pucci B; Milone MR; Ciardiello C; Franco R; Chianese MI; Rocco M; Di Gennaro E; Leone A; Luciano A; Arra C; Santini D; Caraglia M; Budillon A
    Cell Death Dis; 2013 Oct; 4(10):e878. PubMed ID: 24157872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.